Table 2.
Summary of publications describing the impact of HU on increased tricuspid regurgitant velocity, pulmonary hypertension, and pulmonary complications in patients with sickle cell disease
Follow-up times are given as mean or median as reported by each study. Values for TRV are shown in meters per second and values for mPAP are shown in millimeters of mercury. N/A indicates not applicable.
*Included patients with HbSC and/or HbSβ+-thalassemia in addition to HbSS and HbSb0-thalassemia.
†HU use assessed at time of initial TRV or RHC evaluation (single time point).
‡Included only patients with HbSβ+-thalassemia or HbSβ0-thalassemia.
§Total length of study follow-up (mean/median not reported).
‖Method of diagnosing pulmonary hypertension not specified.
